RxDoctor Payments Data

Jamie Meyer

Family · Renton, WANPI 1194200667

Payments from drug & device makers

$2,510in general payments, 2019–2025

Across 31 payments — averaging $80.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$844
  • Johnson & Johnson$424
  • Edwards Lifesciences$380
  • Paragonix Technologies, Inc.$314
  • Shockwave Medical, Inc$180
  • Abbott$143
  • plus $226 from 5 others

What the payments were for

  • Food & beverage$2,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,510 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$23,671
Medicare patients
270
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban298$435,847
XareltoRivaroxaban122$164,383
EntrestoSacubitril/Valsartan89$119,722
JardianceEmpagliflozin49$70,892
FarxigaDapagliflozin Propanediol41$51,670
Repatha SureclickEvolocumab31$42,863
BrilintaTicagrelor29$22,076
Praluent PenAlirocumab22$17,905
Metoprolol Succinate613$8,760
Atorvastatin Calcium477$5,326
Bumetanide54$3,132
Losartan Potassium256$3,068
Diltiazem 24hr Er (Cd)Diltiazem Hcl110$2,698
Carvedilol254$2,661
Furosemide355$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$424$164,383122 claims
NovartisEntresto$30$119,72289 claims
AstraZenecaFarxiga, Brilinta$844$73,74670 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.

Other family in Renton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →